Indication

In combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy.

Medicine details

Medicine name:
encorafenib (Braftovi)
SMC ID:
SMC2312
Pharmaceutical company
Pierre Fabre Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
Q1 2021
SMC meeting date:
Q1 2021
Patient group submission deadline:
30 November 2020